Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AKRO 
Akero Therapeutics Inc (AKRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: AKRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $56
1 Year Target Price $56
| 9 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.57% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.50B USD | Price to earnings Ratio - | 1Y Target Price 56 |
Price to earnings Ratio - | 1Y Target Price 56 | ||
Volume (30-day avg) 12 | Beta -0.41 | 52 Weeks Range 21.34 - 58.40 | Updated Date 12/4/2025 |
52 Weeks Range 21.34 - 58.40 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.9323 | Actual -0.99 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.63% | Return on Equity (TTM) -34.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3748746593 | Price to Sales(TTM) - |
Enterprise Value 3748746593 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.77 | Shares Outstanding 82324445 | Shares Floating 69950643 |
Shares Outstanding 82324445 | Shares Floating 69950643 | ||
Percent Insiders 1.46 | Percent Institutions 112.45 |
Upturn AI SWOT
Akero Therapeutics Inc
Company Overview
History and Background
Akero Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017 and is based in South San Francisco, California. It focuses on developing transformational medicines for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH).
Core Business Areas
- NASH Drug Development: Akero focuses on developing therapies to treat NASH. Their lead product candidate is efruxifermin (EFX), a fibroblast growth factor 21 (FGF21) analogue designed to reduce liver fat and improve metabolic parameters in NASH patients.
Leadership and Structure
Andrew Cheng, M.D., Ph.D., is the President and CEO. The company has a management team with expertise in drug development and commercialization.
Top Products and Market Share
Key Offerings
- Efruxifermin (EFX): Efruxifermin (EFX) is Akero's lead product candidate for treating NASH. It's currently in Phase 2b clinical trials. Market share data is not yet applicable as the drug is not approved. Competitors include Madrigal Pharmaceuticals (resmetirom) and Viking Therapeutics (VK2809). EFX revenue is currently zero.
Market Dynamics
Industry Overview
The NASH market is a large and growing market with a high unmet medical need. The prevalence of NASH is increasing due to rising rates of obesity and diabetes. Several companies are developing drugs for NASH, making it a competitive landscape.
Positioning
Akero is positioned as a key player in the NASH market with its EFX drug candidate. Their competitive advantage lies in the potential efficacy and safety profile of EFX based on early clinical data.
Total Addressable Market (TAM)
The NASH market is estimated to be worth billions of dollars. Estimates for the total market value range from $35 billion to $50 billion. Akero is positioned to capture a significant portion of this market if EFX is approved.
Upturn SWOT Analysis
Strengths
- Promising clinical trial results for EFX
- Strong management team
- Focus on a high unmet medical need (NASH)
- Proprietary FGF21 analogue technology
Weaknesses
- EFX is still in clinical development
- Reliance on a single product candidate
- High cash burn rate associated with clinical trials
- No revenue generation yet
Opportunities
- Positive clinical trial outcomes leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into other metabolic diseases
- Advancements in diagnostic tools for NASH
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other NASH drugs
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
Competitive Landscape
Akero operates in a competitive landscape with several other companies developing NASH drugs. Its competitive advantage lies in the potential efficacy and safety of its EFX drug candidate.
Growth Trajectory and Initiatives
Historical Growth: As a clinical-stage company, historical growth is measured by the advancement of EFX through clinical trials and the securing of funding.
Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential approval and commercialization of EFX. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include ongoing Phase 2b clinical trials for EFX and exploration of potential partnerships.
Summary
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing EFX for NASH. The company has shown promising results in clinical trials, but faces risks associated with clinical development and regulatory approval. Akero needs to successfully navigate clinical trials and secure funding to continue its development efforts. Efficacy and safety against key competitors is essential for a good market outcome.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Akero Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akero Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Dr. Andrew Cheng M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://akerotx.com |
Full time employees 74 | Website https://akerotx.com | ||
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.